GLP1R and type 2 diabetes mellitus: This 12-week randomised, placebo-controlled, active-referenced phase 1b study evaluated the safety, tolerability, pharmacokinetics and efficacy of IBI362, a balanced once-weekly GLP-1 and glucagon receptor dual agonist, in Chinese patients with T2D.